{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Autosomal dominant mutations in the human Leucine-Rich Repeat Kinase 2 (LRRK2) gene represent the most common monogenetic cause of Parkinson disease (PD) and increased kinase activity observed in pathogenic mutants of LRRK2 is most likely causative for PD-associated neurotoxicity.",
          "judgment": "Yes",
          "reasoning": "The paper states that LRRK2 mutations are a common cause of Parkinson's disease and suggests that increased kinase activity of LRRK2 mutants is causative for PD-associated neurotoxicity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The sequence of the LRRK2 kinase domain shows similarity to MAP kinase kinase kinases. Furthermore, LRRK2 shares highest sequence homology with mixed linage kinases which act upstream of canonical MAPKK and are involved in cellular stress responses. Therefore, we addressed the question if LRRK2 exhibits MAPKKK activity by systematically testing MAPKKs as candidate substrates, in vitro. We demonstrate that LRRK2 variants phosphorylate mitogen-activated protein kinase kinases (MAPKK), including MKK3 -4, -6 and -7.",
          "judgment": "Yes",
          "reasoning": "The kinase activity assay used in this study is relevant to the disease mechanism as it investigates the phosphorylation of MAPKKs by LRRK2, which is related to cellular stress responses and neurotoxicity.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "LRRK2 aliquots were incubated with 2 µg of indicated substrate protein in 30 µL assay buffer ... supplemented with 50 μΜ MgATP ... The reaction mix was incubated for 2 h at 30°C. The reaction was stopped by addition of 10 µL 5 × Laemmli buffer and samples were incubated for 2 min at 96°C prior to SDS gel-electrophoresis and western blotting. ... Autoradiograms were obtained by exposure of phospho-imager plates to the membranes which were then quantified by a Typhoon Trio Reader (GE-Healthcare). The signals were normalised to LRRK2 levels determined by Ponceau staining and western blotting.",
          "judgment": "Yes",
          "reasoning": "A kinase-dead variant (K1906M) was used as a negative control, and wild-type was included. The experiments were repeated. The presence of both negative and positive controls, along with multiple replicates, satisfies the requirements of this step.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The later two variants have mutations within the kinase domain of LRRK2. For various disease-associated LRRK2 variants an increased autokinase activity as well as increased phosphotransfer rates towards the generic substrate myelin basic protein and the potential endogenous substrate moesin were reported. However, only the G2019S mutation has been consistently found to increase LRRK2 kinase activity.",
          "judgment": "No",
          "reasoning": "The paper does not explicitly state that known pathogenic or benign variants were used as controls in this specific MAPKKK assay. While they compare activity to other mutants, they don't state known pathogenicity for those comparisons, independently validated.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "For the comparison of different LRRK2 mutants, at least four independent data points were used for each mutant and differences in phosphorylation levels were probed for statistical significance by analysis of variance (ANOVA). Pair-wise comparison was performed by Tukey's post-hoc test. LRRK2 phosphorylation was normalised to the average of LRRK2 wild-type phosphorylation levels which were set as 100%.",
          "judgment": "No",
          "reasoning": "While the authors performed statistical tests (ANOVA, Tukey's post-hoc), they did not calculate or report an OddsPath value.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Various disease-associated LRRK2 variants",
          "judgment": "Yes",
          "reasoning": "There are less than 10 variants",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The LRRK2 G2019S mutant shows increased phosphorylation of MKK6 compared to wild-type, supporting its role as a pathogenic variant with increased kinase activity. However, the evidence is limited to 'supporting' due to the absence of known benign/pathogenic control variants and OddsPath calculation, and with less than 10 controls."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Autosomal dominant mutations in the human Leucine-Rich Repeat Kinase 2 (LRRK2) gene represent the most common monogenetic cause of Parkinson disease (PD) and increased kinase activity observed in pathogenic mutants of LRRK2 is most likely causative for PD-associated neurotoxicity.",
          "judgment": "Yes",
          "reasoning": "The paper states that LRRK2 mutations are a common cause of Parkinson's disease and suggests that increased kinase activity of LRRK2 mutants is causative for PD-associated neurotoxicity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The sequence of the LRRK2 kinase domain shows similarity to MAP kinase kinase kinases. Furthermore, LRRK2 shares highest sequence homology with mixed linage kinases which act upstream of canonical MAPKK and are involved in cellular stress responses. Therefore, we addressed the question if LRRK2 exhibits MAPKKK activity by systematically testing MAPKKs as candidate substrates, in vitro. We demonstrate that LRRK2 variants phosphorylate mitogen-activated protein kinase kinases (MAPKK), including MKK3 -4, -6 and -7.",
          "judgment": "Yes",
          "reasoning": "The kinase activity assay used in this study is relevant to the disease mechanism as it investigates the phosphorylation of MAPKKs by LRRK2, which is related to cellular stress responses and neurotoxicity."
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "LRRK2 aliquots were incubated with 2 µg of indicated substrate protein in 30 µL assay buffer ... supplemented with 50 μΜ MgATP ... The reaction mix was incubated for 2 h at 30°C. The reaction was stopped by addition of 10 µL 5 × Laemmli buffer and samples were incubated for 2 min at 96°C prior to SDS gel-electrophoresis and western blotting. ... Autoradiograms were obtained by exposure of phospho-imager plates to the membranes which were then quantified by a Typhoon Trio Reader (GE-Healthcare). The signals were normalised to LRRK2 levels determined by Ponceau staining and western blotting.",
          "judgment": "Yes",
          "reasoning": "A kinase-dead variant (K1906M) was used as a negative control, and wild-type was included. The experiments were repeated. The presence of both negative and positive controls, along with multiple replicates, satisfies the requirements of this step.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The later two variants have mutations within the kinase domain of LRRK2. For various disease-associated LRRK2 variants an increased autokinase activity as well as increased phosphotransfer rates towards the generic substrate myelin basic protein and the potential endogenous substrate moesin were reported. However, only the G2019S mutation has been consistently found to increase LRRK2 kinase activity.",
          "judgment": "No",
          "reasoning": "The paper does not explicitly state that known pathogenic or benign variants were used as controls in this specific MAPKKK assay. While they compare activity to other mutants, they don't state known pathogenicity for those comparisons, independently validated.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "For the comparison of different LRRK2 mutants, at least four independent data points were used for each mutant and differences in phosphorylation levels were probed for statistical significance by analysis of variance (ANOVA). Pair-wise comparison was performed by Tukey's post-hoc test. LRRK2 phosphorylation was normalised to the average of LRRK2 wild-type phosphorylation levels which were set as 100%.",
          "judgment": "No",
          "reasoning": "While the authors performed statistical tests (ANOVA, Tukey's post-hoc), they did not calculate or report an OddsPath value.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The increase in MKK6 phosphorylation observed for these LRRK2 variants is in the same range as the increase in autokinase activity",
          "judgment": "Yes",
          "reasoning": "There are less than 10 variants",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The LRRK2 I2020T mutant shows a slight increase in phosphorylation of MKK6 compared to wild-type, suggesting its role as a pathogenic variant with increased kinase activity. However, the evidence is limited to 'supporting' due to the absence of known benign/pathogenic control variants and OddsPath calculation, and with less than 10 controls."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Autosomal dominant mutations in the human Leucine-Rich Repeat Kinase 2 (LRRK2) gene represent the most common monogenetic cause of Parkinson disease (PD) and increased kinase activity observed in pathogenic mutants of LRRK2 is most likely causative for PD-associated neurotoxicity.",
          "judgment": "Yes",
          "reasoning": "The paper states that LRRK2 mutations are a common cause of Parkinson's disease and suggests that increased kinase activity of LRRK2 mutants is causative for PD-associated neurotoxicity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The sequence of the LRRK2 kinase domain shows similarity to MAP kinase kinase kinases. Furthermore, LRRK2 shares highest sequence homology with mixed linage kinases which act upstream of canonical MAPKK and are involved in cellular stress responses. Therefore, we addressed the question if LRRK2 exhibits MAPKKK activity by systematically testing MAPKKs as candidate substrates, in vitro. We demonstrate that LRRK2 variants phosphorylate mitogen-activated protein kinase kinases (MAPKK), including MKK3 -4, -6 and -7.",
          "judgment": "Yes",
          "reasoning": "The kinase activity assay used in this study is relevant to the disease mechanism as it investigates the phosphorylation of MAPKKs by LRRK2, which is related to cellular stress responses and neurotoxicity."
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "LRRK2 aliquots were incubated with 2 µg of indicated substrate protein in 30 µL assay buffer ... supplemented with 50 μΜ MgATP ... The reaction mix was incubated for 2 h at 30°C. The reaction was stopped by addition of 10 µL 5 × Laemmli buffer and samples were incubated for 2 min at 96°C prior to SDS gel-electrophoresis and western blotting. ... Autoradiograms were obtained by exposure of phospho-imager plates to the membranes which were then quantified by a Typhoon Trio Reader (GE-Healthcare). The signals were normalised to LRRK2 levels determined by Ponceau staining and western blotting.",
          "judgment": "Yes",
          "reasoning": "A kinase-dead variant (K1906M) was used as a negative control, and wild-type was included. The experiments were repeated. The presence of both negative and positive controls, along with multiple replicates, satisfies the requirements of this step.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The Roc-domain mutant LRRK2 R1441C showed no significant alteration in its kinase activity",
          "judgment": "No",
          "reasoning": "The paper does not explicitly state that known pathogenic or benign variants were used as controls in this specific MAPKKK assay. While they compare activity to other mutants, they don't state known pathogenicity for those comparisons, independently validated.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "For the comparison of different LRRK2 mutants, at least four independent data points were used for each mutant and differences in phosphorylation levels were probed for statistical significance by analysis of variance (ANOVA). Pair-wise comparison was performed by Tukey's post-hoc test. LRRK2 phosphorylation was normalised to the average of LRRK2 wild-type phosphorylation levels which were set as 100%.",
          "judgment": "No",
          "reasoning": "While the authors performed statistical tests (ANOVA, Tukey's post-hoc), they did not calculate or report an OddsPath value.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "in contrast to the kinase domain mutants, the Roc domain mutant LRRK2 R1441C showed no significant alteration in kinase activity",
          "judgment": "Yes",
          "reasoning": "There are less than 10 variants",
          "next_step_or_outcome": "Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_supporting"
      },
      "overall_conclusion": "The LRRK2 R1441C Roc-domain mutant does not show significant changes in kinase activity compared to wild type, which supports a Benign assessment with a maximum supporting evidence strength."
    }
  ]
}
